A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield

Abstract

Our results strongly indicate that for molecular diagnosis of heterogeneous disorders such as NMDs, targeted panel testing has the highest clinical yield and should therefore be the preferred first-tier approach.